Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 31.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,701 shares of the company’s stock after selling 7,259 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Moderna were worth $1,049,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Commerzbank Aktiengesellschaft FI increased its stake in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC increased its stake in shares of Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC increased its stake in shares of Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares during the period. McAdam LLC increased its stake in shares of Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after acquiring an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC increased its stake in shares of Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after acquiring an additional 160 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 13.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 2,930 shares of company stock valued at $217,170. Insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on MRNA shares. TD Cowen dropped their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday. Finally, Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Stock Performance

NASDAQ:MRNA opened at $36.94 on Thursday. The firm has a 50 day simple moving average of $56.98 and a 200-day simple moving average of $95.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) earnings per share. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.